the aid library

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (130)

View PDF (213)

Pharmacological interventions for anxiety disorders in children and adolescents

World Health Organization WHO World Health Organization (2012) C_WHO

Q 12: In children and adolescents with anxiety disorders, what is the effectiveness and safety, considering system issues in low- and middle-income countries, of using pharmacological interventions in non-specialist settings?

Download (210)

View PDF (184)

Management of Gambling Disorders

Ministry of Health, Singapore (2011) CC

MOH clinical practice guidelines

Download (187)

View PDF (150)

COVID-19 Treatment Guidelines

National Department of Health, South Africa (2022) CC

Updated Treatment Guidelines

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (96)

View PDF (149)

Consideraciones sobre el uso de antivirales, anticuerpos monoclonales y otras intervenciones para el manejo de pacientes con COVID-19 en América Latina y el Caribe

Organización Mundial de la Salud OMS (2022) C_WHO

26 de abril del 2022. La Organización Panamericana de la Salud presenta estas consideraciones con el fin de apoyar la toma de decisiones relativa al manejo de pacientes con COVID-19 en la Región de las Américas. Las recomendaciones tienen en cuenta la evidencia más reciente, el estado de vacunac... more

Download (3880)

View PDF (3183)

Where there is no psychiatrist : a mental health care manual

Patel, Vikram Royal College of Psychiatrists (2003) C2

This book is a practical manual of mental health care for community health workers, primary care nurses, social workers and primary care doctors, particularly in developing countries.Helpful features include: over 50 illustrations and case studies, jargon-free explanations and descriptions, flow-cha... more

List of Medicines for Ethiopia

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia (2010) C1

6th edition

Pharmacological treatment of mental disorders in primary health care

World Health Organization WHO (2009) CC

The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalised anxiety and sleep disorders; obsessive-compulsive disorders and panic attacks; and alcohol and opioid dependence

List of Medicines for Community Pharmacy, Ethiopia (LMCP)

Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA) (2012) C1

Fourth Edition

Formulary of Narcotic Drugs and Psychotropic Substances for Ethiopia

Drug Administration and Control Authority (DACA) of Ethiopia (2004) C1

Download (147)

View PDF (239)

Bipolar Disorder. Parents’ Medication Guide for Bipolar Disorder in Children & Adolescents

American Academy of Child and Adolescent Psychiatry (2010) CC

This guide was developed by AACAP to give reliable information about medication used to treat bipolar disorder in children and adolescents to parents whose children have been diagnosed with the illness.

External Link

Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment

Lancaster, C.L., Teeters, J.B., Gros, D.F., Back, S.E. Journal of Clinical Medicine (2016) CC

Abstract: Posttraumatic stress disorder (PTSD) is a chronic psychological disorder that can develop after exposure to a traumatic event. This review summarizes the literature on the epidemiology, assessment, and treatment of PTSD. We provide a review of the characteristics of PTSD along with associa... more

External Link

Cognitive functioning in major depression – a summary

Åsa Hammar and Guro Årdal (2009) CC

Front. Hum. Neurosci., 25 September 2009 | https://doi.org/10.3389/neuro.09.026.2009

External Link

Post Traumatic Stress Disorder in Children Sexsual Abuse

Eglantina Dervishi Academic Journal of Interdisciplinary Studies MCSER Publishing (2015) CC

The aim of this study is to research deeply on the post-traumatic stress disorder in sexually abused children. Proving the presence of forms of the disorder in children and the their treatment mode will be in the center of the study. The methods used to conduct this study will be a literature review... more